Analysis of the therapeutic effect of budesonide combined with compound ipratropium bromide nebulization inhalation on emergency severe asthma ‌
布地奈德联合复方异丙托溴铵雾化吸入治疗急诊重症哮喘的疗效分析

摘要

目的 探讨布地奈德联合复方异丙托溴铵雾化吸入治疗急诊重症哮喘的临床疗效。方法 选取2023年1月—2024年12月我院急诊科收治的120例重症哮喘患者，按随机数字表法分为两组，对照组采用布地奈德单一雾化吸入治疗，观察组采用布地奈德联合复方异丙托溴铵雾化吸入治疗。比较两组临床疗效、症状缓解时间、肺功能指标、炎症因子水平及不良反应发生率。结果 观察组治疗总有效率及FEV₁、FEV₁/FVC、PEF指标高于对照组，喘息缓解、呼吸困难改善、咳嗽减轻时间和IL-6、TNF-α、CRP水平均短于对照组（P<0.05）；两组不良反应发生率比较（P>0.05）。结论 布地奈德联合复方异丙托溴铵雾化吸入治疗急诊重症哮喘疗效显著，可快速缓解症状，改善肺功能，降低炎症反应，且安全性良好，值得临床推广。

Abstract

Objective To explore the clinical efficacy of budesonide combined with compound ipratropium bromide nebulization inhalation in the treatment of emergency severe asthma.
Methods 120 severe asthma patients admitted to the emergency department of our hospital from January 2023 to December 2024 were randomly divided into two groups using a random number table. The control group was treated with budesonide single nebulization inhalation, while the observation group was treated with budesonide combined with compound ipratropium bromide nebulization inhalation. Compare the clinical efficacy, symptom relief time, lung function indicators, levels of inflammatory factors, and incidence of adverse reactions between two groups.
Results The total effective rate and FEV₁, FEV₁/FVC, PEF indicators of the observation group were higher than those of the control group. The time for relief of wheezing, improvement of dyspnea, cough relief, and the levels of IL-6, TNF - α, and CRP were all shorter in the observation group than in the control group (P<0.05); Comparison of the incidence of adverse reactions between the two groups (P>0.05).
Conclusion   The combination of budesonide and compound ipratropium bromide nebulization inhalation has significant therapeutic effects on emergency severe asthma, can quickly relieve symptoms, improve lung function, reduce inflammatory reactions, and has good safety. It is worthy of clinical promotion.